免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展

doi:10.11904/j.issn.1002-3070.2017.04.012

摘要/Abstract

摘要： 免疫检查点抑制剂(Immune-checkpoint blockers,ICBs)治疗已在多种肿瘤中获得了较好的疗效,患者生活质量明显改善。然而,并不是所有接受ICBs治疗的病人在病灶控制、症状改善和生存时间等方面均获益,很多患者对首次使用ICBs治疗一段时间后出现的耐药现象,是目前临床面临的难题。本综述列举了原发性耐药和获得性耐药可能的原因。原发性耐药包括肿瘤微环境、癌细胞本身及其他相关因素;获得性耐药包括非经典的免疫共抑制分子继发性过表达、抗原提呈信号通路异常及T细胞活化杀伤功能异常等。并阐述了可能存在的多种新型联合治疗方式,包括联合放化疗及联合靶向治疗等措施。

关键词: 肿瘤免疫治疗, 免疫检查点抑制剂, 原发性耐药, 获得性耐药

Abstract: Immune-checkpoint blockers(ICBs)have been well received in a variety of tumors,and the quality of patient life has improved significantly.However,the reasons why not all patients treated with ICBs benefit from lesion control,symptom improvement,and survival time.Many patients are resistant to the first time when they have been using ICBs for a period of time.This is a clinical challenge.This review lists possible causes of primary drug resistance and acquired resistance to ICBs.The primary resistance is associated with several mechanisms,including tumor microenvironment,cancer cells themselves and other related factors.The acquired resistance includes nonclassical immunoprecipitation molecules secondary overexpression,abnormalities of antigen presenting signal pathway and dysfunction of T cell activation killer.Finally,we have described a variety of possible new combination of treatment,including combined radiotherapy and chemotherapy,and combined targeted therapy with other measures.

Key words: Cancer immunotherapy, Immune-checkpoint blockers, Primary drug resistance, Acquired drug resistance

中图分类号:

R734.2

曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.

ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
2 Joyce JA,Fearon DT.T cell exclusion,immune privilege,and the tumor microenvironment[J].Science,2015,348(6230):74-80.
3 Kelderman S,Schumacher TN,Haanen JB.Acquired and intrinsic resistance in cancer immunotherapy[J].Molecular Oncology,2014,8(6):1132-1139.
4 O′Donnell JS,Long GV,Scolyer RA,et al.Resistance to PD1/PDL1 checkpoint inhibition[J].Cancer Treatment Reviews,2017,52:71-81.
5 Robert C,Thomas L,Bondarenko I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526.
6 Hamid O,Robert C,Daud A,et al.Safety and tumor re-sponses with lambrolizumab(anti-PD-1)in melanoma[J].N Engl J Med,2013,369(2):134-144.
7 Hanahan D,Coussens LM.Accessories to the crime:functions of cells recruited to the tumor microenvironment[J].Cancer Cell,2012,21(3):309-322.
8 Coussens LM,Zitvogel L,Palucka AK.Neutralizing tumor-promoting chronic inflammation:a magic bullet?[J].Science,2013,339(6117):286-291.
9 Holmgaard RB,Zamarin D,Munn DH,et al.Indoleamine 2,3-dioxygenase is a critical resistance mechanismin anti-tumor T cell immunotherapy targeting CTLA-4[J].J Exp Med,2013,210(7):1389-1402.
10 Nagarsheth N,Peng D,Kryczek I,et al.PRC2 epigenetically silences Th1-Type chemokines to suppress effector T-cell trafficking in colon cancer[J].Cancer Res,2016,76(2):275-282.
11 Diamond MS,Kinder M,Matsushita H,et al.Type I interferon is selectively required by dendritic cells for immune rejection of tumors[J].J Exp Med,2011,208(10):1989-2003.
12 Fuertes MB,Kacha AK,Kline J,et al.Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells[J].J Exp Med,2011,208(10),2005-2016.
13 Spranger S,Bao R,Gajewski TF.Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity[J].Nature,2015,523(7559):231-235.
14 Ansell SM,Lesokhin AM,Borrello I,et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin′s lymphoma[J].N Engl J Med,2015,372(4):311-319.
15 Chen N,Fang W,Zhan J,et al.Up-regulation of PD-L1 by egfr activation mediates the immune escape in GFR-driven NSCLC:Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J].J Thorac Oncol,2015,10(6):910-923.
16 Zelenay S,van der Veen AG,Bottcher JP,et al.Cyclooxygenase-dependent tumor growth through evasion of immunity[J].Cell,2015,162(6):1257-1270.
17 Chang CH,Qiu J,O′Sullivan D,et al.Metabolic competition in the tumor microenvironment is a driver of cancer progression[J].Cell,2015,162(6):1229-1241.
18 Yang W,Bai Y,Xiong Y,et al.Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism[J].Nature,2016,531(7596),651-655.
19 Rizvi NA,Hellmann MD,Snyder A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.
20 Le DT,Uram JN,Wang H,et al.PD-1 blockade in tumors with mismatch-repair deficiency[J].N Engl J Med,2015,372(26):2509-2520.
21 Rizvi NA,Hellmann MD,Snyder A,et al.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.
22 Melero I,Lasarte JJ.Genetic basis for clinical response to CTLA-4 blockade[J].N Engl J Med,2015,372(8):783.
23 Yadav M,Jhunjhunwala S,Phung QT,et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature,2014,515(7528):572-576.
24 Gubin MM,Zhang X,Schuster H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.
25 Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus Docetaxel in advancedsquamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
26 Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(3):123-135.
27 Ilie M,Long-Mira E,Bence C,et al.Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances:a potential issue for anti-PD-L1 therapeutic strategies[J].Ann Oncol,2016,27(1):147-153.
28 Kataoka K,Shiraishi Y,Takeda Y,et al.Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers[J].Nature,2016,534(7607):402-406.
29 Gao J,Shi LZ,Zhao H,et al.Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy[J].Cell,2016,167(2):397-404.
30 Pitt JM,Vetizou M,Daillere R,et al.Resistance mechanisms to immune-checkpoint blockade in cancer:tumor-intrinsic and-extrinsic factors[J].Immunity,2016,44(6):1255-1269.
31 Zaretsky JM,Garcia-Diaz A,Shin DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma[J].N Engl J Med,2016,375(9):819-829.
32 Koyama S,Akbay EA,Li YY,et al.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints[J].Nature Communications,2016,7:10501.
33 Miao D,Adeegbe D,Rodig SJ,et al.Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma:Genomic,neoantigen,and immunohistochemical evaluation[J].Chicago:ASCO Annual Meeting,2016.
34 Vatner RE,Cooper BT,Vanpouille-Box C,et al.Combinations of immunotherapy and radiation in cancer therapy[J].Front Oncol,2014,4:325.
35 Twyman-Saint Victor C,Rech AJ,Maity A,et al.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.
36 Bernstein MB,Krishnan S,Hodge JW,et al.Immunotherapy and stereotactic ablative radiotherapy(ISABR):a curative approach?[J].Nature Reviews Clinical Oncology,2016,13(8):516-524.
37 Twyman-Saint Victor C,Rech AJ,Maity A,et al.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.
38 Antonia SJ,Brahmer JR,Gettinger SN,et al.Nivolumab(anti-PD-1;BMS-936558,ONO-4538)in combination with platinum-based doublet chemotherapy(PT-DC)in advanced non-small cell lung cancer(NSCLC)[J].Chicago:ASCO Annual Meeting,2015.
39 Vincent J,Mignot G,Chalmin F,et al.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J].Cancer Res,2010,70:3052-3061.
40 Tesniere A,Schlemmer F,Boige V,et al.Immunogenic death of colon cancer cells treated with oxaliplatin[J].Oncogene,2010,29(4):482-491.
41 Hughes PE,Caenepeel S,Wu LC.Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer[J].Trends Immunol,2016,37(7):462-476.
42 Sharma P,Allison JP.Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential[J].Cell,2015,161(2):205-2144.
43 Wahid M,Akhter N,Jawed A,et al.Pembrolizumab′s non-cross resistance mechanism of action successfully overthrown ipilimumab[J].Crit Rev Oncol Hematol,2017,111:1-6.
44 Spagnolo F,Ghiorzo P,Orgiano L,et al.BRAF-mutant melanoma:treatment approaches,resistance mechanisms,and diagnostic strategies[J].Onco Targets Ther,2015,8:157-168.
45 Oxnard GR,Ramalingam SS,Ahn M,et al.Preliminary results of TATTON,a multi-arm phase Ib trial of AZD9291 combined with MEDI4736,AZD6094 or selumetinib in EGFR-mutant lung cancer[J].Chicago:ASCO Annual Meeting,2015.
46 Wolchok JD,Kluger H,Callahan MK,et al.Nivolumab plus ipilimumab in advanced melanoma[J].N Engl J Med,2013,369(2):122-133.
47 Topalian SL,Taube JM,Anders RA,et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J].Nat Rev Cancer,2016,16(5):275-287.
48 Puzanov I,Milhem MM,Minor D,et al.Talimogene laherparepvec in combination with ipilimumab in previously untreated,unresectable stage ⅢB-Ⅳ melanoma[J].J Clin Oncol,2016,34(22):2619-2626.
49 Chapuis AG,Roberts IM,Thompson JA,et al.T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression[J].J Clin Oncol,2016[Epub ahead of print].

[1]	王孟菲, 许波群. 局部晚期宫颈癌免疫治疗进展[J]. 实用肿瘤学杂志, 2025, 39(2): 157-161.
[2]	何佳颖, 朱津丽, 贾凯旋, 杨佩颖. IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 330-335.
[3]	韩晶, 关泉林. 肿瘤相关中性粒细胞在免疫检查点抑制剂耐药中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 349-354.
[4]	赵璐, 张正凤, 王大臻, 杨柳, 刘泽, 娄长杰. 免疫治疗在实体瘤中的应用现状[J]. 实用肿瘤学杂志, 2024, 38(1): 55-61.
[5]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[6]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[7]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[8]	杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.
[9]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[10]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[11]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[12]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[13]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[14]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[15]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.